Barclays PLC upgraded shares of Mylan N.V. (NASDAQ:MYL) from an equal weight rating to an overweight rating in a research report sent to investors on Monday, May 22nd, MarketBeat.com reports. They currently have $50.00 price target on the stock, up from their previous price target of $47.00.

Other equities research analysts have also issued reports about the company. Royal Bank of Canada set a $41.00 target price on Mylan N.V. and gave the stock a hold rating in a research report on Saturday, May 13th. Cowen and Company reaffirmed a market perform rating and issued a $43.00 target price (down from $55.00) on shares of Mylan N.V. in a research report on Sunday, May 21st. Guggenheim reaffirmed a neutral rating on shares of Mylan N.V. in a research report on Friday, March 3rd. Leerink Swann reaffirmed an outperform rating on shares of Mylan N.V. in a research report on Monday, March 20th. Finally, Mizuho reaffirmed a buy rating and issued a $47.00 target price on shares of Mylan N.V. in a research report on Tuesday, February 28th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $50.77.

Mylan N.V. (NASDAQ:MYL) traded down 0.70% during mid-day trading on Monday, reaching $36.72. 8,784,868 shares of the company’s stock traded hands. Mylan N.V. has a 52 week low of $33.60 and a 52 week high of $50.40. The stock has a market capitalization of $19.68 billion, a PE ratio of 36.68 and a beta of 1.23. The stock’s 50 day moving average is $38.54 and its 200-day moving average is $38.99.

Mylan N.V. (NASDAQ:MYL) last posted its quarterly earnings results on Wednesday, May 10th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.92 by $0.01. The business had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.81 billion. Mylan N.V. had a return on equity of 23.69% and a net margin of 4.59%. The business’s revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.76 EPS. On average, equities analysts anticipate that Mylan N.V. will post $5.19 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Mylan N.V. (MYL) Upgraded at Barclays PLC” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/06/16/mylan-myl-raised-to-overweight-at-barclays-plc-updated-updated.html.

In related news, President Rajiv Malik sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the completion of the transaction, the president now owns 799,855 shares in the company, valued at approximately $31,994,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Laboratories Abbott sold 44,000,000 shares of Mylan N.V. stock in a transaction on Thursday, March 23rd. The shares were sold at an average price of $41.60, for a total value of $1,830,400,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 44,035,000 shares of company stock valued at $1,831,800,000 in the last 90 days. 0.69% of the stock is owned by corporate insiders.

Institutional investors have recently modified their holdings of the stock. Mangrove Partners acquired a new position in shares of Mylan N.V. during the third quarter valued at about $7,624,000. Hsbc Holdings PLC increased its position in shares of Mylan N.V. by 77.8% in the third quarter. Hsbc Holdings PLC now owns 21,102 shares of the company’s stock valued at $798,000 after buying an additional 9,232 shares during the last quarter. Zacks Investment Management increased its position in shares of Mylan N.V. by 2.5% in the third quarter. Zacks Investment Management now owns 160,300 shares of the company’s stock valued at $6,111,000 after buying an additional 3,969 shares during the last quarter. Commonwealth Bank of Australia increased its position in shares of Mylan N.V. by 6.8% in the third quarter. Commonwealth Bank of Australia now owns 29,727 shares of the company’s stock valued at $1,133,000 after buying an additional 1,900 shares during the last quarter. Finally, Zweig DiMenna Associates LLC acquired a new position in shares of Mylan N.V. during the third quarter valued at about $221,000. Hedge funds and other institutional investors own 69.95% of the company’s stock.

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.